Cassava Sciences reported $47.33M in Current Liabilities for its fiscal quarter ending in June of 2025.


Current Liabilities Change Date
Abbott USD 13.44B 435M Jun/2025
Amgen USD 20.48B 2.53B Jun/2025
Biogen USD 3.18B 2.11B Jun/2025
Cassava Sciences USD 47.33M 35.58M Jun/2025
Eisai JPY 411.61B 39.31B Jun/2025
Eli Lilly USD 39.02B 8.95B Jun/2025
Geron USD 64.28M 1.25M Jun/2025
J&J USD 56.9B 6.58B Mar/2025
Merck USD 26.04B 863M Jun/2025
Novartis USD 31.71B 95M Jun/2025
Pfizer USD 37.73B 1.27B Jun/2025
Roche Holding CHF 27.02B 424M Dec/2024